MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

CCT196969

CAS No. : 1163719-56-9

MCE 站：CCT196969

产品活性：CCT196969 是一种泛-Raf 抑制剂，抑制 B-Raf，BRaf^V600E 和 CRAF，IC₅₀ 分别为 0.1, 0.04, 和 0.01 μM。

研究领域：MAPK/ERK Pathway

作用靶点：Raf

In Vitro: CCT196969 is a pan-Raf inhibitor with anti-SRC activity. CCT196969 is an orally available, well-tolerated B-Raf inhibitor that directly inhibits B-Raf^V600E in cells. CCT196969 inhibits B-Raf at 100 nM and B-Raf^V600E at 40 nM. It inhibits CRaf at 12 nM, SRC at 26 nM, and LCK at 14 nM. CCT196969 is active against melanoma and colorectal cancer cell lines that are mutant for B-Raf. CCT196969 induces caspase 3 and PARP cleavage, demonstrating that it induces apoptosis.

In Vivo: CCT196969 is extremely well tolerated and does not produce any significant adverse effects in vivo. It inhibits the growth of NRAS mutant DO4 tumor xenografts in nude mice. CCT196969 inhibits ERK and SRC and induce tumor regression in a PDX from the resistant tumor without causing body weight loss in the mice.

相关产品：Covalent Screening Library Plus  |  Bioactive Compound Library Plus  |  Immunology/Inflammation Compound Library  |  Kinase Inhibitor Library  |  MAPK Compound Library  |  Anti-Cancer Compound Library  |  Covalent Screening Library  |  Oxygen Sensing Compound Library  |  Ferroptosis Compound Library  |  Glutamine Metabolism Compound Library  |  Anti-Lung Cancer Compound Library  |  Anti-Pancreatic Cancer Compound Library  |  Doramapimod  |  GW 5074  |  Ro 5126766  |  AZ 628  |  GDC-0879  |  ZM 336372  |  Agerafenib  |  Raf inhibitor 1  |  AZ304  |  L-779450  |  MCP110  |  Sorafenib (D3)  |  Raf inhibitor 2

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。